Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

Clinical Pharmacokinetics

Volumn 36, Issue SUPPL. 1, 1999, Pages 1-11

  Cass, Lindsey M R ^a   Efthymiopoulos, Constantin ^a   Bye, Alan ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZANAMIVIR;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; VERTIGO; VOMITING;

EID: 0032996541     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936001-00001     Document Type: Article

References (14)

1. 1. Von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase based inhibitors of influenza virus replication. Nature 1993; 363: 418-23
2. 2. Whittington A, Bethell R. Recent developments in the antiviral therapy of influenza. Expert Opin Ther Patents 1995; 5: 793-803
3. 3. Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9
4. 4. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet 1999; 36 Suppl. 1: 41-50
5. 5. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982
6. 6. Kaulbach HC, White MV, Igarashi Y, et al. Estimation of nasal epithelial lining fluid using urea as a marker. J Allergy Clin Immunol 1993; 92 (3): 457-65
7. 7. Newman SP, Pavia D. Aerosol deposition in man. In: Moren F, Newhouse MT, Dolovich MB, editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier Science, 1985: 289-312
8. 8. Newman SP, Clarke SW. Aerosols in therapy. In: Moren F, Newhouse MT, Dolovich MB, editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier Science, 1985: 193-217
9. 9. Cass LMR, Efthymiopoulos C, Marsh J, et al. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet 1999; 36 Suppl. 1: 13-9
10. 10. Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A infection. Antimicrob Agents Chemother. In press
11. 11. Peng A, Hussey B, Moss J. A GG167 pharmacokinetic study to select a regimen for prophylaxis. Research Triangle Park: Glaxo Wellcome, RM 1997/00419/00
12. 12. Calfee DP, Peng AW, Hussey EK, et al. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection. Antiviral Ther. In press
13. 13. Cass LMR, Brown J, Pickford M. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. I: 21-31
14. 11C|zanamivir following administration as an intranasal spray: evaluation with positron emission tomography. Clin Pharmacokinet 1999; 36 Suppl. I: 33-9